Cetoacidosis diabética euglicémica asociada a inhibidor de cotransportador de sodio glucosa Tipo 2 en paciente con diabetes Mellitus Tipo 1
Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. report of one case with type 1 diabetes
Rev. méd. Chile; 145 (3), 2017
Publication year: 2017
Diabetic ketoacidosis with mild hyperglycemia is a major complication of sodium-glucose cotransporter 2 inhibitors. Although its use is not approved for patients with type 1 diabetes mellitus, the drug is often prescribed with the hope of optimizing metabolic control. We report a 20 years old female with hypothyroidism and type 1 diabetes consulting for vomiting and abdominal pain. The patient had used canagliflozin during the two previous months. Laboratory showed a blood glucose of 200 mg/dl, a severe metabolic acidosis (pH 7.1) and ketonemia. The patient was successfully treated in the intensive care unit.
Canagliflozina/efectos adversos, Cetoacidosis Diabética/inducido químicamente, Hiperglucemia/inducido químicamente, Hipoglucemiantes/efectos adversos, Canagliflozina/uso terapéutico, Diabetes Mellitus Tipo 1/tratamiento farmacológico, Cetoacidosis Diabética/diagnóstico, Hiperglucemia/diagnóstico, Hipoglucemiantes/uso terapéutico, Inhibidores del Cotransportador de Sodio-Glucosa 2